Company reaches quarterly sales of $6.1 million, up 228% year over year and up 101% sequentially

 First quarter of positive net income in Company’s history fueled by robust market demand, increased brand awareness and improved cannabis production

Gross margin improvement from 32% to 49% reflects increased operating efficiencies

Completed the acquisition of ONE Cannabis Group, parent company of national dispensary franchise Unity Rd., complementing the Company’s innovative, premium product portfolio with a platform for national distribution

 Management to host conference call and webcast to discuss key operational and financial highlights today at 11:00 AM ET

PHOENIX – May 18, 2021 – Item 9 Labs Corp. (OTCQX: INLB) (“Item 9 Labs” or the “Company”), a vertically integrated cannabis dispensary franchisor and operator that produces premium products, today reported operating and financial results for the three months ended March 31, 2021, the Company’s second quarter for fiscal year 2021 (“Q2 FY2021”). The Company will be hosting an earnings call on May 18, 2021 at 11:00 AM Eastern time (8:00 AM Pacific time).

Key Financial Highlights for Q2 FY2021 (compared with Q2 FY2020)

• Revenue increased 228% to $6.1 million
• Gross profit increased 403% to $3.0 million
• Gross margin increased to 49% from 32%
• Operating income of $0.5 million (compared with operating loss of $0.9 million)
• Operating expenses as a percentage of revenue declined to 40% from 80%
• Net income of $49,020 (compared with net loss of $1.6 million)
• Adjusted EBITDA of $1.0 million (compared with adjusted EBITDA loss of $0.9 million)

Key Business Highlights during and subsequent to Q2 FY2021

• Completed the acquisition of ONE Cannabis Group (OCG Inc.), parent company of leading U.S. cannabis dispensary franchisor Unity Rd., differentiating the Company by combining its premium products with a strong retail franchise and a national distribution platform
• Unity Rd. signed agreements with three entrepreneurial groups for dispensary franchise expansion into New Jersey, in addition to a multi-unit franchise agreement with development underway in Michigan and Ohio
• Launched Orion 710 pod system, an innovative vaporization device for medical and adult-use consumers, featuring swappable one-gram pods filled with live resin blends and a USB-C rechargeable battery

Management Commentary

With the successful passage of Proposition 207 for adult use in Arizona, the state started transitioning from a medical-only into a far-larger adult-use marijuana market on January 22, 2021. Industry analysts expect the state’s total legal marijuana market will near $1.5 billion in the next three years.

“We’re seeing the impact of the strong market demand with record-breaking revenues for our premium products, reporting $6.1 million during the quarter. That’s more than double our revenues from last quarter and 228% higher than the same quarter last year,” commented Item 9 Labs Chief Executive Officer Andrew Bowden. “This quarter represents a milestone for us as it also marks our first quarter of profitability. Across the company, our team continues to execute more efficiently and manage our costs while increasing production to meet product demand.”

“We completed our acquisition of OCG Inc. during the quarter, giving us unique capabilities in franchising and positioning us for rapid scalability at reduced capital requirements, as dispensaries will be owned and operated by local franchise partners. Franchising facilitates the expansion of our national retail footprint through Unity Rd. while also serving as a distribution platform for our in-house production, enabling us to capture additional market share,” Bowden said. “We also plan to develop or partner with cultivation facilities in states where Unity Rd. franchise partners open cannabis retail shops. Already, Unity Rd. has signed multiple agreements with more than 10 entrepreneurial groups who are developing the brand across at least seven states. We are seeing growth in our franchise pipeline as lead flows and interest increase with the easing regulatory environment and state-level legalization.”

“Our planned cultivation site expansion, the first phase of which is expected to break ground soon, along with our cannabis franchising offering and the favorable regulatory climate are the catalysts that we believe will propel Item 9 Labs’ revenue and market share growth going forward,” added Bowden.

The Company completed its acquisition of OCG Inc. in March 2021, creating one of the first vertically integrated cannabis franchise companies in the country. Colorado-based OCG Inc. is the parent company of dispensary franchise Unity Rd. The combination brings differentiating retail franchising capabilities to Item 9 Labs, including helping new entrepreneurs and existing operators navigate the complex cannabis industry by providing training, resources, and ongoing support needed to compliantly and successfully operate a dispensary. The reduced capital expenditure (CapEx) franchise model positions the Company to accelerate scale for both the Unity Rd. franchise and Item 9 Labs product brands, as dispensaries will be locally owned and operated by cannabis entrepreneurs.

Item 9 Labs recently launched the Orion 710 pod system – a next-generation vape system that provides full-spectrum flower experiences on the go. Available as one-gram Grounded, Orbit, and Beyond pods, the handheld, portable vaporization system debuted in March 2021 to medical and adult-use marijuana consumers in Arizona. Consisting of a rechargeable battery designed to fit discreetly in hand and easily swappable one-gram pods filled with a choice of live resin blends, the Orion currently stands as the only device with its unique characteristics. Orion’s slightly larger size allows for greater modifications, leading to increased battery life, 20% more cannabinoids per draw, and a five-second draw cutoff. The technology also best suits the viscosity of Item 9 Labs live resin, making for smoother inhales and improved overall experience.

Unity Rd. inked agreements with three entrepreneurial groups for New Jersey franchise expansion, in addition to a multi-unit franchise agreement with development underway in Michigan and Ohio. Unity Rd. is guiding the New Jersey partners through the dispensary license process as the state is expected to open license applications as early as late 2021. Each group will be pursuing at least one dispensary license to open a Unity Rd. shop in the state. Annual retail sales of the adult-use New Jersey market are expected to grow to as much as $950 million by 2024. Unity Rd.’s new multi-unit franchise partner, who is developing three shops across the Michigan and Ohio markets, is seeking immediate entrance by purchasing an existing dispensary to convert into a Unity Rd. as well as applying for dispensary licenses. The team is already working to identify potential acquisition opportunities across the two states as part of its support. In addition, Unity Rd. will provide guidance to these franchise partners by sharing its accumulated knowledge and resources to compliantly and successfully operate a dispensary.

Financial Results for Q2 FY2021 Ended March 31, 2021:

• Revenue: For the three months ended March 31, 2021, revenue was $6.1 million, an increase of $4.2 million, or 228%, compared with $1.9 million for the three months ended March 31, 2020. This increase was primarily due to higher market demand, with the Company increasing production in response.

• Gross Profit: For the three months ended March 31, 2021, gross profit was $3.0 million, an increase of $2.4 million, or 403%, compared with $0.6 million for the three months ended March 31, 2020. The resulting gross margin was 49%, compared with 32% for the same quarter last year. The increase in gross margin is due to the Company operating more efficiently during its production expansion.

• Management believes costs will continue to increase at a lower rate than revenue growth and production in future periods, which is expected to lead to higher profit margins than historical figures illustrate. The Company has been able to lower marginal costs since the first half of fiscal year 2020 and expects to see gross profit margins continue to increase in future periods.

• Total Operating Expenses: For the three months ended March 31, 2021, total operating expenses were $2.5 million, an increase of $1.0 million, or 66%, compared with $1.5 million for the same quarter last year. Operating expenses as a percentage of revenue decreased to 40% from 80% for the quarters compared, reflecting the Company’s focus on increasing revenue, reducing expenses, and performing more efficiently. Management believes this ratio will decrease going forward as revenues continue to grow at a higher rate than operating expenses.

• Of note, $0.4 million of the Company’s operating expenses for the three months ended March 31, 2021 were non-cash expenses, including depreciation, amortization and stock-based compensation.

• Operating Income: For the three months ended March 31, 2021, operating income was $0.5 million, an improvement of $1.4 million, compared with an operating loss of $0.9 million for the same quarter last year.

• Adjusted EBITDA: After adding back non-cash operating expenses, depreciation and amortization, interest and stock-based compensation, Adjusted EBITDA for the three months ended March 31, 2021 was $1.0 million, as compared with an Adjusted EBITDA loss of $0.9 million for the same quarter last year.

• Net Income: For the three months ended March 31, 2021, net income attributable to Item 9 Labs was $49,020, or break-even per share, compared with a net loss of $1.6 million, or a net loss of $0.03 per share, for the three months ended March 31, 2020.

• Cash: Cash and cash equivalents totaled $4.3 million as of March 31, 2021.

Financial Results for the Six Months Ended March 31, 2021:

• Revenue: For the six months ended March 31, 2021, revenue was $9.2 million, an increase of $5.8 million, or 170%, compared with $3.4 million for the same period last year. This increase was primarily due to higher market demand driving increased production.

• Gross Profit: For the six months ended March 31, 2021, gross profit was $4.4 million, an increase of $3.3 million, or 311%, compared with $1.1 million for the same period last year. The resulting gross margin was 48%, compared with 32% for the same period last year.

• Total Operating Expenses: For the six months ended March 31, 2021, total operating expenses were $4.3 million, an increase of $1.1 million, or 35%, compared with $3.2 million for the same period last year. Operating expenses as a percentage of revenue decreased to 47% from 93% for the periods compared.

• Of note, $1.2 million of the Company’s operating expenses for the six months ended March 31, 2021 were non-cash expenses, including depreciation, amortization and stock-based compensation.

• Operating Income: For the six months ended March 31, 2021, operating income was $0.2 million, an improvement of $2.2 million, compared with an operating loss of $2.1 million for the same period last year.

• Adjusted EBITDA: After adding back non-cash operating expenses, depreciation and amortization, interest and stock-based compensation, Adjusted EBITDA for the six months ended March 31, 2021 was positive $1.3 million, as compared with a loss of $1.2 million for the same period last year.

• Net Loss: For the six months ended March 31, 2021, net loss attributable to Item 9 Labs was $1.0 million, or $0.02 per share, compared with $3.5 million, or $0.06 per share, for the same period last year.

The Company filed its Form 10-Q on May 17, 2021. Click here to view.

Conference Call and Webcast Information – May 18, 2021 at 11:00 AM ET (8:00 AM PT)

Chief Executive Officer Andrew Bowden, Chief Financial Officer Bobby Mikkelsen and Chief Franchise Officer Mike Weinberger will host the Company’s Q2 FY2021 earnings call today at 11:00 AM Eastern time.

Date: Tuesday, May 18, 2021

Time: 11:00 AM Eastern time (8:00 AM Pacific time)

Access by phone: Please call the conference telephone number 10-15 minutes prior to the start time. An operator will register your name and organization.

U.S. dial-in number: 888-506-0062 (pass code: 665448)

International number: 973-528-0011 (pass code: 665448)

Access by webcast: A live and archived webcast will be available. Click on this webcast link to register.

Questions: Please submit questions to jayne@item9labs.com before the earnings call begins. The management team will do their best to answer all questions.

A telephonic replay of the conference call will also be available until Tuesday, June 1, 2021 via the following call-in numbers:

Toll-free replay number: 877-481-4010 (replay pass code: 41183)

International replay number: 919-882-2331 (replay pass code: 41183)

Adjusted EBITDA

Use of Non-GAAP Financial Measures

To supplement the Company’s financial statements presented on a GAAP basis, Item 9 Labs provides Adjusted EBITDA as a supplemental measure of its performance.

To provide investors with additional insight and allow for a more comprehensive understanding of the information used by management in its financial and decision-making surrounding pro forma operations, Item 9 Labs supplements its consolidated financial statements presented on a basis consistent with U.S. generally accepted accounting principles, or GAAP, with Adjusted EBITDA as a non-GAAP financial measure of earnings. Adjusted EBITDA represents EBITDA plus stock-based compensation and change in fair value of derivative liabilities. Item 9 Labs management uses Adjusted EBITDA as a financial measure to evaluate the profitability and efficiency of the business model. The Company uses these non-GAAP financial measures to assess the strength of the underlying operations of the business. These adjustments, and the non-GAAP financial measures that are derived from them, provide supplemental information to analyze its operations between periods and over time. Item 9 Labs finds this especially useful when reviewing pro forma results of operations, which include large non-cash amortizations of intangible assets from acquisitions and stock-based compensation. Investors should consider its non-GAAP financial measures in addition to, and not as a substitute for, financial measures prepared in accordance with GAAP.

About Item 9 Labs Corp. 

Item 9 Labs Corp. (OTCQX: INLB) is a vertically integrated cannabis operator delivering premium products from its large-scale cultivation and production facilities in the United States. The award-winning Item 9 Labs brand specializes in best-in-class products and user experience across several cannabis categories. With substantial insider investment, the Company brings the best industry practices to markets nationwide through distinctive retail experience, cultivation capabilities, and production innovation. The veteran management team combines a diverse skill set with deep experience in the cannabis sector and capital markets to lead a new generation of public cannabis companies that provide transparency, consistency, and well-being. Headquartered in Arizona, the Company has 650,000+ square feet of operations space under development on its 50-acre site, one of the largest properties in Arizona zoned to grow and cultivate flower. For additional information, visit item9labscorp.com.

Forward-Looking Statements

This press release contains forward-looking statements within the meaning of the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Such statements involve risks and uncertainties, including, but not limited to, risks and effects of legal and administrative proceedings and governmental regulation, especially in a foreign country, future financial and operational results, competition, general economic conditions, proposed transactions that are not legally binding obligations of the company and the ability to manage and continue growth. Should one or more of these risks or uncertainties materialize, or should underlying assumptions prove incorrect, actual outcomes may vary materially from those indicated. Important factors that could cause actual results to differ materially from the forward-looking statements we make in this news release include the introduction of new technology, market conditions and those set forth in reports or documents we file from time to time with the SEC. We undertake no obligation to revise or update such statements to reflect current events or circumstances after the date hereof or to reflect the occurrence of unanticipated events.

###

Media Contact:

Item 9 Labs

Jayne Levy, Director of Communications

Email: Jayne@item9labs.com

Investor Contact:

Item 9 Labs

800-403-1140
Email: investors@item9labs.com

SOURCE:  Item 9 Labs Corp.

Acquisition of ONE Cannabis Group, Parent Company of Dispensary Franchise Unity Rd., Paves a New Path of Industry Innovation as the Leading National Vertically Integrated Cannabis Franchise Company

Phoenix, AZ – March 23, 2021 – Item 9 Labs Corp. (OTCQX: INLB) (“Item 9 Labs” or the “Company”), a vertically integrated cannabis operator that produces premium products, today announced the closing of its acquisition of ONE Cannabis Group (“OCG Inc.”), parent company of cannabis dispensary franchise Unity Rd. The combination creates a differentiated business model that offers premium products and distribution through an expanding network of dispensary franchises. Resulting synergies and benefits from the transaction include expanded business offering and expertise, operational efficiencies, cost savings, and revenue upside. Additionally, the acquisition creates new opportunities in the cannabis sector by providing solutions to industry challenges commonly faced by existing business owners, prospective entrepreneurs, and consumers.

Item 9 Labs produces award-winning and best-in-class products from its large-scale cultivation site and production facilities. Headquartered in Arizona, the Company is expanding its operations space by 650,000+ square feet on its 50-acre site, one of the largest properties in Arizona zoned to grow and cultivate flower. It also owns and operates DispensaryPermits.com and DispensaryTemplates.com, leading online platforms for information surrounding cannabis business applications, regulations and state updates. Colorado-based OCG Inc. brings the stability, scalability, and brand continuity of franchising to the budding and fragmented world of cannabis through its retail franchise Unity Rd. Named one of the top cannabis retail leaders in the nation by MJBizDaily magazine and the first cannabis business to earn a Franchise Times Dealmakers award, OCG Inc. helps eager participants enter the complex industry with ease by leveraging its legal cannabis business experience and trusted resources under the distinct Unity Rd. brand.

“Blending our premium, experiential cannabis brand with a true dispensary franchise model puts Item 9 Labs in a unique position to capitalize on opportunities in a dynamic and rapidly evolving regulatory environment. ONE Cannabis Group perfectly complements and enhances our existing offerings by creating a built-in platform for national distribution of our products and brands through the Unity Rd. franchise network,” said Item 9 Labs CEO Andrew Bowden. “Having immediate entry points into states where Unity Rd. is building presence is expected to drive margin expansion across multiple markets and strengthen our profitability.”

This acquisition creates one of the first vertically integrated cannabis franchises in the U.S. The reduced capital expenditure (CapEx) franchise model provides accelerated scale for Item 9 Labs and Unity Rd., while keeping dispensaries locally owned and operated. In contrast to existing multi-state operators (MSOs), the franchise model requires reduced corporate capital requirements for development of the dispensary brand, as franchisees own and operate their own businesses. Unity Rd. franchise partners benefit from the continued guidance and tools provided by the franchisor while being able to scale more rapidly, compared with operating independently.

“Unity Rd. is the safest way for entrepreneurs to enter the cannabis industry,” said Mike Weinberger, Chief Operating Officer of OCG Inc., who is now appointed Chief Franchise Officer of Item 9 Labs Corp. and named to the Company’s Board of Directors with this announcement. “Extending our in-house knowledge in dispensary license applications and operations as well as having direct access to Item 9 Labs’ deep bench of trusted, award-winning products are expanded benefits for Unity Rd. franchise partners, positioning them ahead of any competition.”

Transaction Highlights

The transaction offers differentiation in franchising, retail, cultivation, production, and license application. The combined company is committed to growing the Unity Rd. dispensary franchise network and introducing Item 9 Labs products in states where the franchise is expanding its footprint, while continuing to enhance its production and cultivation sites.

Reduced CapEx and Rapid Scalability with Unity Rd. Franchise Model: Franchising offers one of the most viable solution for industry newcomers and existing operators navigating the complex cannabis landscape. Unity Rd. launched in 2018 and currently has multiple agreements signed with 10 entrepreneurial groups that are developing the brand across six states. The franchisor provides the knowledge, resources, and ongoing support its franchise partners need for compliant and successful dispensary operations. Dispensary franchises are expected to drive the cannabis industry forward by mitigating barriers and encouraging local ownership. As a vertically integrated cannabis franchisor, the Company is in a unique position for accelerated scale across both the Unity Rd. and Item 9 Labs brands. Unity Rd. franchise partners sign a 10-year agreement and pay a $100,000 franchise fee up front with 5% gross royalty on top-line revenue and a 2% marketing royalty fee. Further, low corporate capital is required for national development, as franchisees own and operate their own businesses.

Retail Footprint Driven by Strong Lead Flow with Experience at Every Step: The combined team has a proven track record of winning cannabis licenses in 15 states. Bringing together the DispensaryPermits.com and DispensaryTemplates.com customer base, which generated nearly 12,000 application and partnership leads in 2020, with the 2,500-plus prospective franchisees Unity Rd. sees annually is expected to escalate franchise development efforts. DispensaryPermits.com and DispensaryTemplates.com customers will now have a solution for long-term guidance and support through the Unity Rd. franchise opportunity. With news of the acquisition as well as increased U.S. cannabis legalization, Unity Rd. has seen a surge in franchise lead activity over the past six months. The dispensary franchise is currently targeting Arizona, Colorado, Maine, Michigan, New Jersey, and Oklahoma among other markets, as part of its strategic franchise expansion plan.

Robust National Distribution Platform Supporting In-House Production: Item 9 Labs products are currently available in 43% of Arizona’s cannabis dispensaries. Through this existing retail partner network and the Unity Rd. franchise platform, the combined company will have the most sustainable product distribution platform in cannabis. Unity Rd. franchise partners benefit from direct access to Item 9 Labs’ premium, lab-tested products that have earned more than a dozen industry awards, including multiple top marks in Arizona’s leading cannabis competition. The product suite spans 75-plus active cannabis strains and more than 150 differentiated cannabis products as well as premium concentrates along with Apollo and Orion technologies – next-generation vape systems that provide full-spectrum flower experiences on the go. The Unity Rd. retail footprint eases barriers to entry for currently produced consumer products suites in new markets, allowing for increased revenue in product licensing, wholesale, and franchise royalties.

Experienced Leadership Team Delivers Unrivaled Depth of Bench: The combined veteran management team brings a diverse skill set with deep experience in the cannabis sector, franchising, and the capital markets to lead a new generation of public cannabis companies. The team collectively has more than 120 years of legal cannabis industry experience and 50-plus years in franchising, in addition to earning 20-plus franchise and cannabis industry accolades. OCG Inc.’s team had previously developed and sold a global 500-unit franchise business to Kahala Brands, awarded 300-plus franchises in more than five countries, and supported the development of 100-plus franchise companies.

The Agreement

Item 9 Labs shall issue 19,080,000 shares of Item 9 Labs Common Stock, subject to deductions indicated in the Agreement and Plan of Merger (the “Merger Agreement”), in consideration for all of OCG Inc.’s Common Stock. The holders of OCG Inc. Shares will hold approximately 25% of Item 9 Labs’ issued and outstanding shares.

Following the merger, Item 9 Labs will continue as parent and OCG Inc. will be a wholly owned subsidiary of the Company. Andrew Bowden will remain as CEO.

ABOUT ITEM 9 LABS CORP.:

Item 9 Labs Corp. (OTCQX: INLB) is a vertically integrated cannabis operator and dispensary franchisor delivering premium products from its large-scale cultivation and production facilities in the United States. The award-winning Item 9 Labs brand specializes in best-in-class products and user experience across several cannabis categories. The company also offers a unique dispensary franchise model through the national Unity Rd. retail brand. Easing barriers to entry, the franchise provides an opportunity for both new and existing dispensary owners to leverage the knowledge, resources, and ongoing support needed to thrive in their state compliantly and successfully. Item 9 Labs brings the best industry practices to markets nationwide through distinctive retail experience, cultivation capabilities, and product innovation. The veteran management team combines a diverse skill set with deep experience in the cannabis sector, franchising, and the capital markets to lead a new generation of public cannabis companies that provide transparency, consistency, and well-being. Headquartered in Arizona, the company is currently expanding its operations space by 650,000+ square feet on its 50-acre site, one of the largest properties in Arizona zoned to grow and cultivate flower. For additional information, visit item9labscorp.com.

FORWARD-LOOKING STATEMENT:

This press release contains forward-looking statements within the meaning of the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Such statements involve risks and uncertainties, including, but not limited to, risks and effects of legal and administrative proceedings and governmental regulation, especially in a foreign country, future financial and operational results, competition, general economic conditions, proposed transactions that are not legally binding obligations of the company and the ability to manage and continue growth. Should one or more of these risks or uncertainties materialize, or should underlying assumptions prove incorrect, actual outcomes may vary materially from those indicated. Important factors that could cause actual results to differ materially from the forward-looking statements we make in this news release include the introduction of new technology, market conditions and those set forth in reports or documents we file from time to time with the SEC. We undertake no obligation to revise or update such statements to reflect current events or circumstances after the date hereof or to reflect the occurrence of unanticipated events.

Media Contact:

Item 9 Labs

Jayne Levy, Director of Communications

Email: Jayne@unityrd.com

Investor Contact:

Item 9 Labs

800-403-1140
Email: investors@item9labs.com

SOURCE:  Item 9 Labs Corp.

Revenue growth fueled by strong market demand and increases in cannabis production

Gross margin improvement reflects increased operating efficiencies

Company is poised for accelerated revenue growth in 2021, driven by adult-use legalization in Arizona, approved expansion plans for cultivation in Arizona, and additional distribution channels through merger with ONE Cannabis Group – parent company of national dispensary franchise Unity Rd.

Phoenix, AZ – February 16, 2021 – Item 9 Labs Corp. (OTCQX: INLB) (“Item 9 Labs” or the “Company”), a vertically integrated cannabis operator that produces premium products, today reported operating and financial results for the three months ended December 31, 2020, the Company’s first quarter for fiscal year 2021 (“Q1 FY2021”).

Key Financial Highlights for Q1 FY2021 (compared with Q1 FY2020)

• Revenue increased 98% to $3.0 million
• Gross profit increased 195% to $1.4 million
• Gross margin increased 15% to 47%
• Operating loss decreased 70% to $0.4 million
• Operating expenses as a percentage of revenue declined from 110% to 59%
• Positive Adjusted EBITDA of $0.4 million increased by $1.1 million from a loss of $0.7 million

Key Business Highlights for Q1 FY2021

• Finalized merger agreement with ONE Cannabis Group (“OCG Inc.”), to add unique franchising capabilities and significantly enhance the Company’s retail distribution network, in December 2020; expected to close in early 2021
• Received approval for 45-acre marijuana cultivation site expansion in Coolidge, Arizona in November 2020
• Arizona’s Proposition 207 Adult-Use Cannabis Initiative successfully passed in November 2020

Management Commentary

“We are extremely pleased with our strong first-quarter performance, as we continued to grow revenues and improve margins and profitability,” commented Item 9 Labs Chief Executive Officer Andrew Bowden. “Our results exceeded our internal projections, with sequential quarter-over-quarter revenue growth rate of 21% and positive adjusted EBITDA of $0.4 million.”

With the successful passage of Proposition 207 for adult use in Arizona, it is expected that the state’s total legal marijuana market will near $1.5 billion in the next three years.

“The high penetration of our award-winning products in existing Arizona dispensaries, coupled with operational expansion, puts us in strong position to capture additional market share,” said Bowden, adding that the first phase of cultivation site expansion will increase the Company’s operational footprint by more than 300% and create 60 jobs in the next 12 months. He continued, “Our expansion plans and streamlined production process have us well-prepared for the year ahead.”

“Outside of Arizona development, we look forward to closing our pending merger with ONE Cannabis Group and their cannabis franchise Unity Rd.,” said Bowden. “The business combination is expected to increase our branded product footprint via national distribution through the Unity Rd. dispensary franchise platform. It will also add a predictable recurring revenue stream through franchise royalty fees.”

Item 9 Labs’ 45-acre marijuana cultivation site expansion was approved by Coolidge, Arizona officials in November 2020. Local city council supports the Company’s master site expansion plan that will create 650,000+ square feet of marijuana operations. Known for its award-winning, premium cannabis products, Item 9 Labs is projected to expand its operations space by more than 3,000% and create more than 200 jobs by the conclusion of the development. Currently, the Company has two 10,000-square-foot facilities on its 50-acre site. The site will see expansion on 45 of its acres to include six additional buildings, 12 greenhouses and six greenhouse support buildings (head houses). Seven of the buildings will be for indoor cultivation and one will be for expansion of the Company’s lab and support space for finished product. In addition to the above uses, the Company is currently awaiting state approval for five acres of on-site outdoor cultivation. Upon breaking ground, ongoing construction will take place over three years in six phases, with the initial phase beginning in early 2021. Phase one includes the construction of two 26,000-square-foot greenhouses, one head house and two 10,000-square-foot buildings – one for indoor cultivation and one for the lab and packaging. This phase adds 72,000 square feet of operations space. Construction on phase two is anticipated to begin in summer 2021.

The Company finalized its merger agreement with ONE Cannabis Group (OCG Inc.) in December 2020 and expects to close the merger in early 2021; the Definitive 14C Proxy was filed on February 3, 2021. Based in Colorado, ONE Cannabis Group is the parent company of dispensary franchise Unity Rd. The cannabis franchise pioneer helps entrepreneurial and existing operators enter and navigate the complex cannabis industry with ease by offering its franchise partners the training, resources, and ongoing support needed to compliantly and successfully operate a dispensary. Currently, Unity Rd. has agreements signed for the development of more than two dozen franchisee owned and operated shops across multiple states.

Financial Results for Q1 FY2021, Ended December 31, 2020:

• Revenue: For the three months ended December 31, 2020, revenue was $3.0 million, an increase of $1.5 million, or 98%, compared with $1.5 million for the three months ended December 31, 2019. This increase was primarily due to increased production outputs, supported by operational improvements, as product demand grew.

• Gross Profit: For the three months ended December 31, 2020, gross profit was $1.4 million, an increase of $0.9 million, or 195%, compared with $0.5 million for the three months ended December 31, 2019. The resulting gross margin was 47%, compared with 32% for the same quarter last year.

The increase in gross profit was due to the ramp-up in production and continued improvement in the operating capacity of the Company’s cultivation and processing facilities. With the Company’s continued production expansion and focus on operational efficiencies and cost reduction, management expects gross profit to continue to grow going forward.

Management believes costs of revenues will increase at a lower rate than revenues in future periods, which is expected to lead to higher profit margins than historical figures illustrate. Through bulk purchasing, production efficiencies, and investments in equipment, management believes that the Company will continue to improve gross profit margins.

• Total Operating Expenses: For the three months ended December 31, 2020, total operating expenses were $1.8 million, an increase of $0.1 million, or 7%, compared with $1.7 million for the same quarter last year. Operating expenses as a percentage of revenue decreased from 110% to 59% for the quarters compared. Management believes this ratio will decrease going forward as the expectation is that revenues will continue to grow at a higher rate than operating expenses.

Of note, $0.7 million of the Company’s operating expenses for the three months ended December 31, 2020 were non-cash expenses, including depreciation, amortization and stock-based compensation.

• Operating Loss: For the three months ended December 31, 2020, operating loss was $0.4 million, a decrease of $0.8 million, or 70%, compared with operating loss of $1.2 million for the same quarter last year.

• Adjusted EBITDA: After adding back non-cash operating expenses, depreciation and amortization, interest and stock-based compensation, Adjusted EBITDA for the three months ended December 31, 2020 was positive $0.4 million, as compared with a loss of $0.7 million for the same quarter last year.

• Net Loss: For the three months ended December 31, 2020, net loss was $1.1 million, a decrease of $0.9 million, or 46%, compared with $2.0 million for the three months ended December 31, 2019. Loss per share for the three months ended December 31, 2020 was $0.02 per share, compared with loss per share of $0.03 per share for the same quarter last year.

The Company filed its Form 10-Q on February 16, 2021. Click here to view.

Use of Non-GAAP Financial Measures

To supplement the Company’s financial statements presented on a GAAP basis, Item 9 Labs provides Adjusted EBITDA as a supplemental measure of its performance.

To provide investors with additional insight and allow for a more comprehensive understanding of the information used by management in its financial and decision-making surrounding pro forma operations, Item 9 Labs supplements its consolidated financial statements presented on a basis consistent with U.S. generally accepted accounting principles, or GAAP, with Adjusted EBITDA as a non-GAAP financial measure of earnings. Adjusted EBITDA represents EBITDA plus stock-based compensation and change in fair value of derivative liabilities. Item 9 Labs management uses Adjusted EBITDA as a financial measure to evaluate the profitability and efficiency of the business model. The Company uses these non-GAAP financial measures to assess the strength of the underlying operations of the business. These adjustments, and the non-GAAP financial measures that are derived from them, provide supplemental information to analyze its operations between periods and over time. Item 9 Labs finds this especially useful when reviewing pro forma results of operations, which include large non-cash amortizations of intangible assets from acquisitions and stock-based compensation. Investors should consider its non-GAAP financial measures in addition to, and not as a substitute for, financial measures prepared in accordance with GAAP.

About Item 9 Labs Corp. 

Item 9 Labs Corp. (OTCQX: INLB) is a vertically integrated cannabis operator delivering premium products from its large-scale cultivation and production facilities in the United States. The award-winning Item 9 Labs brand specializes in best-in-class products and user experience across several cannabis categories. With substantial insider investment, the Company brings the best industry practices to markets nationwide through distinctive retail experience, cultivation capabilities, and production innovation. The veteran management team combines a diverse skill set with deep experience in the cannabis sector and capital markets to lead a new generation of public cannabis companies that provide transparency, consistency, and well-being. Headquartered in Arizona, the Company has 650,000+ square feet of operations space under development on its 50-acre site, one of the largest properties in Arizona zoned to grow and cultivate flower. For additional information, visit item9labscorp.com.

Forward-Looking Statement

This press release contains forward-looking statements within the meaning of the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Such statements involve risks and uncertainties, including, but not limited to, risks and effects of legal and administrative proceedings and governmental regulation, especially in a foreign country, future financial and operational results, competition, general economic conditions, proposed transactions that are not legally binding obligations of the company and the ability to manage and continue growth. Should one or more of these risks or uncertainties materialize, or should underlying assumptions prove incorrect, actual outcomes may vary materially from those indicated. Important factors that could cause actual results to differ materially from the forward-looking statements we make in this news release include the introduction of new technology, market conditions and those set forth in reports or documents we file from time to time with the SEC. We undertake no obligation to revise or update such statements to reflect current events or circumstances after the date hereof or to reflect the occurrence of unanticipated events.

###

Media Contact:

Item 9 Labs

Jayne Levy, Director of Communications

Email: Jayne@unityrd.com

Investor Contact:

Item 9 Labs

800-403-1140
Email: investors@item9labs.com

SOURCE:  Item 9 Labs

• Annual revenue growth of 65% fueled by increases in production and market demand
• Stage is set for 2021 developments across Arizona cannabis product expansion and new distribution through merger with national dispensary franchise

Phoenix, AZ  – January 13, 2021 – Item 9 Labs Corp. (OTCQX: INLB) (“Item 9 Labs” or the “Company”), a vertically integrated cannabis operator that produces premium products, today reported the Company’s operating and financial results for the fiscal year (FY) ended September 30, 2020.

Key Financial Highlights for FY 2020

• Revenue increased 65% to $8.1 million
• Gross profit increased 39% to $3.3 million
• Operating loss decreased 46% to $5.4 million
• Operating expenses as a percentage of gross profit declined from 526% to 265%
• Adjusted EBITDA loss decreased 9% to $2.1 million

Key Business Highlights for FY 2020

• Ramped up cultivation and production operations
• Continued to improve the operating capacity of cultivation and processing facilities
• Signed definitive merger agreement with ONE Cannabis Group
• Named Mike (Mic) Keskey, retired former President of U.S. Retail for Best Buy Co., Inc. (NYSE: BBY), and Doug Bowden, a 30-year consumer electronics veteran with extensive experience in real estate investment and development, to Board of Directors
• Appointed Andrew Bowden as Chief Executive Officer
• Earned one Errl Cup and four 710 Degree Cup awards, Arizona’s largest cannabis competitions
• Qualified to trade on OTCQX Market (upgraded from OTC Pink to OTCQB, then from OTCQB to OTCQX, both in August)

Management Commentary

“This past year has been an exciting and successful time for our team,” commented Item 9 Labs Chief Executive Officer Andrew Bowden. “We’ve seen strong, steady performance with sequential quarter-over-quarter growth rates of nearly 20% since my appointment as CEO at the start of our 2020 fiscal year. Our team continues to exceed expectations and has efficiently ramped production to meet heightened demand for our products, setting the stage for key strategic and operational developments in 2021. We anticipate increased business activities as we continue to pursue opportunities that position the company for growth and profitability.”

Bowden continued, “We are still in the early stages of our growth and are already seeing an acceleration with Arizona’s adult-use marijuana market opening in the first half of 2021, which we estimate will increase our consumer base by 500%. We’re prepared to meet this demand through our streamlined production process and by expanding our operational cultivation footprint by more than 300% in the year ahead.”

“In addition to continued growth in Arizona, we look forward to closing our pending merger with ONE Cannabis Group and their cannabis franchise, Unity Rd. We expect the combination of our premium, award-winning cannabis products with the nation’s leading dispensary franchise will elevate our brand footprint through national distribution across Unity Rd.’s locally owned and operated dispensaries. This will ease new market product entry and create recurring revenue streams through franchise royalty fees,” Bowden concluded.

Subsequent to the End of FY 2020

Item 9 Labs’ 45-acre marijuana cultivation site expansion was approved by Coolidge, Arizona officials in November 2020. Local city council supports the Company’s master site expansion plan that will create 650,000+ square feet of marijuana operations. Known for its award-winning, premium cannabis products, Item 9 Labs is expected to expand its marijuana operations space by more than 3,000% at the conclusion of the expansion. Currently, the Company has two 10,000 square-foot facilities on its 50-acre site. The site will see expansion on 45 of its acres to include six additional buildings, 12 greenhouses and six greenhouse support buildings (head houses). Seven of the buildings will be for indoor cultivation and one will be for expansion of the Company’s lab and support space for finished product. In addition to the above uses, the Company is currently awaiting state approval for five acres of on-site outdoor cultivation. Upon breaking ground, ongoing construction will take place over three years in six phases, with the initial phase beginning in early 2021. Phase one includes the construction of two 26,000 square-foot greenhouses, one head house and two 10,000 square-foot buildings – one for indoor cultivation and one for the lab and packaging. This phase adds 72,000 square feet of operations space. Construction on phase two is anticipated to begin in summer 2021.

The Company finalized its merger agreement with ONE Cannabis Group (OCG Inc.) in December 2020 and expects to close the merger in early 2021. Based in Colorado, ONE Cannabis Group is the parent company to the dispensary franchise Unity Rd. The cannabis franchise pioneer helps eager operators enter the complex cannabis industry with ease by offering its franchise partners the knowledge, resources, and ongoing support needed to compliantly and profitably operate a dispensary. Currently, Unity Rd. has agreements signed for the development of more than two dozen franchisee owned and operated shops across multiple states and expects the first store to open within the next six months.

Item 9 Labs raised $5.667 million in equity at $0.85 per common share in preparation for the cultivation site expansion, recently approved adult-use legislation in Arizona and the ONE Cannabis Group merger.

Financial Results for FY 2020, Ended September 30, 2020:

• Revenue: For the 12 months ended September 30, 2020, revenue was $8.1 million, an increase of $3.2 million or 65%, compared to $4.9 million for the 12 months ended September 30, 2019. This increase was primarily due to operational improvements that increased production outputs as well as an overall increase in monthly sales as product demand grew.

• Gross Profit: For the 12 months ended September 30, 2020, gross profit was $3.3 million, an increase of $0.9 million or 39%, compared to $2.4 million for the 12 months ended September 30, 2019. The resulting gross margin was 41% for the 12 months ended September 30, 2020, compared to 48% for the 12 months ended September 30, 2019.

The increase in gross profit was due to the ramp up in operations and continued improvement in the operating capacity of the Company’s cultivation and processing facilities. With the Company’s continued increase in capacity and focus on efficiencies and cost reduction, management expects gross profit to continue to grow going forward.

Item 9 Labs increased operational efficiency throughout fiscal year 2020, and management believes costs of revenues will increase at a lower rate than revenues in future periods, which will lead to higher profit margins than these historical figures illustrate. Through bulk purchasing, increasing efficiencies in production, and investments in equipment, management believes that the Company will continue to improve gross profit margins.

• Total Operating Expenses: For the 12 months ended September 30, 2020, total operating expenses were $8.7 million, a decrease of $3.8 million, or 30%, compared to $12.5 million for the 12 months ended September 30, 2019. Operating expenses as a percentage of gross profit decreased from 526% to 265% for the years compared. Management believes this ratio will decrease going forward as the expectation is that revenues will continue to grow at a higher rate than operating expenses.

Of note, $0.9 million of the Company’s operating expenses for the year ended September 30, 2020 were depreciation of fixed assets and amortization of other intangible assets, and $0.4 million is a provision for bad debt; management does not believe the latter to be indicative of future results. Additionally, $1.8 million of the Company’s operating expenses in fiscal year 2020 were paid through the issuance of shares of common stock of the Company and employee stock options. $5.8 million of the Company’s operating expenses for the year ended September 30, 2019 were a loss on impairment of goodwill and other intangible assets, and $0.4 million is a provision for bad debt, both items that management does not believe to be indicative of future results. Additionally, $1.1 million of the Company’s operating expenses in 2019 were paid through the issuance of shares of common stock of the Company.

• Operating Loss: For the 12 months ended September 30, 2020, operating loss was $5.4 million, a decrease of $4.7 million, or 46%, compared to operating loss of $10.1 million for the 12 months ended September 30, 2019.

• Adjusted EBITDA Loss: After adding back non-cash operating expenses, depreciation and amortization, interest and stock-based compensation, Adjusted EBITDA loss for the 12 months ended September 30, 2020 was $2.1 million, a decrease of $0.2 million, or 9%, compared to $2.3 million for the 12 months ended September 30, 2019.

• Net Loss: For the 12 months ended September 30, 2020, net loss was $12.3 million, a decrease of $2.4 million, or 24%, compared to $9.9 million for the 12 months ended September 30, 2019. The resulting loss per share for the 12 months ended September 30, 2020 was ($0.20) per share, compared to ($0.16) per share for the twelve months ended September 30, 2019. $2.2 million of the net loss for the 12 months ended September 30, 2020 relates to the warrants issued to debtholders during the year, and $2.6 million relates to the related beneficial conversion features. The five founding members of Item 9 Labs returned 10 million shares to treasury to make the transaction non-dilutive to the remaining shareholders.

Use of Non-GAAP Financial Measures

To supplement the Company’s financial statements presented on a GAAP basis, Item 9 Labs provides Adjusted EBITDA as a supplemental measure of its performance.

To provide investors with additional insight and allow for a more comprehensive understanding of the information used by management in its financial and decision-making surrounding pro forma operations, Item 9 Labs supplements its consolidated financial statements presented on a basis consistent with U.S. generally accepted accounting principles, or GAAP, Adjusted EBITDA as a non-GAAP financial measures of earnings. Adjusted EBITDA represents EBITDA plus stock-based compensation and change in fair value of derivative liabilities. Item 9 Labs management uses Adjusted EBITDA as financial measures to evaluate the profitability and efficiency of the business model. The Company uses these non-GAAP financial measures to assess the strength of the underlying operations of the business. These adjustments, and the non-GAAP financial measures that are derived from them, provide supplemental information to analyze its operations between periods and over time. Item 9 Labs finds this especially useful when reviewing pro forma results of operations, which include large non-cash amortizations of intangible assets from acquisitions and stock-based compensation. Investors should consider its non-GAAP financial measures in addition to, and not as a substitute for, financial measures prepared in accordance with GAAP.

About Item 9 Labs Corp. 

Item 9 Labs Corp. (OTCQX: INLB) is a vertically integrated cannabis operator headquartered in Arizona. The Company creates best-in-class products and canna-business solutions designed to help people become the best versions of themselves. With an award-winning CPG brand and nationally recognized application team, Item 9 Labs improves the cannabis experience while providing transparency, consistency, and well-being for those relying on them. For additional information, please visit: item9labscorp.com.

Forward-Looking Statement

This press release contains forward-looking statements within the meaning of the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Such statements involve risks and uncertainties, including, but not limited to, risks and effects of legal and administrative proceedings and governmental regulation, especially in a foreign country, future financial and operational results, competition, general economic conditions, proposed transactions that are not legally binding obligations of the company and the ability to manage and continue growth. Should one or more of these risks or uncertainties materialize, or should underlying assumptions prove incorrect, actual outcomes may vary materially from those indicated. Important factors that could cause actual results to differ materially from the forward-looking statements we make in this news release include the introduction of new technology, market conditions and those set forth in reports or documents we file from time to time with the SEC. We undertake no obligation to revise or update such statements to reflect current events or circumstances after the date hereof or to reflect the occurrence of unanticipated events.

###

Media Contact:

Item 9 Labs

Jayne Levy, Director of Communications

Email: Jayne@unityrd.com

Investor Contact:

800-403-1140
Email: IR@item9labs.com

SOURCE:  Item 9 Labs Corp.

Expects to Close Merger of ONE Cannabis Group, Parent Company to Dispensary Franchise Unity Rd., in January 2021

Phoenix, AZ – December 16, 2020 – Item 9 Labs Corp. (OTCQX: INLB) (“Item 9 Labs,” or the “Company”), a vertically integrated cannabis operator that produces premium products, announced today that it has finalized its merger agreement with ONE Cannabis Group (OCG, Inc.) and expects to close the merger in January 2021.

ONE Cannabis Group, based in Colorado, is the parent company to the cannabis dispensary franchise Unity Rd. Built up from the legacy of a 10-plus year, award-winning Colorado dispensary & cultivator and infused with decades of franchise experience, the company helps eager operators enter the complex industry with ease. The cannabis franchise pioneer offers its partners the knowledge, resources, and ongoing support needed to compliantly and profitably operate a dispensary. Currently, Unity Rd. has franchise agreements signed for the development of more than two dozen shops across multiple states and expects the first store to open in quarter one 2021.

Recently, it was named one of the top cannabis retail leaders in the nation by MJBizDaily magazine and one of the “Best Cannabis Companies to Work For” in both the dispensary and cultivation categories in Cannabis Business Times’ elite 2020 list. The company is also the first cannabis business to earn a Franchise Times Dealmakers award – a recognition presented to the boldest players driving mergers and acquisitions in franchising. For more information on ONE Cannabis Group, visit ocginc.com and head to unityrd.com for details on the Unity Rd. franchise opportunity.

“Our teams have been working on parallel paths to ensure a smooth integration and are eager to officially operate as one unit. This was a significant milestone for all and we look forward to closing [the merger] in January 2021,” Item 9 Labs’ Chief Executive Officer, Andrew Bowden, commented. “The merger with ONE Cannabis Group greatly enhances our business capabilities with its retail distribution and unique franchise operation. Their business model and national network of Unity Rd. franchise partners create highly predictable, recurring revenue streams.”

About Item 9 Labs Corp.

Item 9 Labs Corp. (OTCQX: INLB) is a vertically integrated cannabis operator headquartered in Arizona. The Company creates best-in-class products and canna-business solutions designed to help people become the best versions of themselves. With an award-winning CPG brand and nationally recognized application team, Item 9 Labs improves the cannabis experience while providing transparency, consistency, and well-being for those relying on them. For additional information, please visit: item9labscorp.com.

Forward-Looking Statement

This press release contains forward-looking statements within the meaning of the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Such statements involve risks and uncertainties, including, but not limited to, risks and effects of legal and administrative proceedings and governmental regulation, especially in a foreign country, future financial and operational results, competition, general economic conditions, proposed transactions that are not legally binding obligations of the company and the ability to manage and continue growth. Should one or more of these risks or uncertainties materialize, or should underlying assumptions prove incorrect, actual outcomes may vary materially from those indicated. Important factors that could cause actual results to differ materially from the forward-looking statements we make in this news release include the introduction of new technology, market conditions and those set forth in reports or documents we file from time to time with the SEC. We undertake no obligation to revise or update such statements to reflect current events or circumstances after the date hereof or to reflect the occurrence of unanticipated events.

Media Contact:

Item 9 Labs

Jayne Levy, Director of Communications

Email: Jayne@unityrd.com

Investor Contact:

ClearThink
Email: nyc@clearthink.capital

Source:  – Item 9 Labs Corp.

Phoenix, AZ – December 8, 2020 – Item 9 Labs Corp. (OTCQX:INLB) (“Item 9 Labs,” or the “Company”), a vertically integrated cannabis operator that produces premium products, today announced that it will be presenting at the 13th annual LD Micro Main Event investor conference on Monday, December 14 at 11am EST. Chief Executive Officer Andrew Bowden will be presenting to a live, virtual audience.

Register here: ve.mysequire.com/

The Main Event will feature a new and unique format, with companies presenting for 10 minutes, followed by 10 minutes of Q&A by a panel of investors and analysts.

“The time has finally come to do something different in the virtual conference world. Let’s see if we can pull off something that can be enjoyed by both executives and investors alike,” stated Chris Lahiji, Founder of LD, now a wholly owned subsidiary of SRAX, Inc.

The Main Event will take place on December 14th and 15th, exclusively on the Sequire Virtual Events platform.

View Item 9 Labs’ profile here: http://www.ldmicro.com/profile/INLB

About LD Micro/SEQUIRE

LD Micro began in 2006 with the sole purpose of being an independent resource to the microcap world. What started as a newsletter highlighting unique companies, has transformed into the pre-eminent event platform in the space. For more information, please visit ldmicro.com.

The upcoming Main Event will be highlighting a new format that will benefit both executives and the investors tuning in from all over the globe.

In September 2020, LD Micro. Inc. was acquired by SRAX, Inc., a financial technology company that unlocks data and insights for publicly traded companies. Through its premier investor intelligence and communications platform, Sequire, companies can track their investors’ behaviors and trends and use those insights to engage current and potential investors across marketing channels. For more information on SRAX, visit srax.com and mysequire.com.

About Item 9 Labs Corp.

Item 9 Labs Corp. (OTCQX: INLB) is a vertically integrated multi-state cannabis operator headquartered in Arizona. The Company creates best-in-class products and canna-business solutions designed to help people become the best versions of themselves. With an award-winning CPG brand and nationally recognized application team, Item 9 Labs improves the cannabis experience while providing transparency, consistency, and well-being for those relying on them. For additional information, please visit: item9labscorp.com.

Forward-Looking Statement

This press release contains forward-looking statements within the meaning of the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Such statements involve risks and uncertainties, including, but not limited to, risks and effects of legal and administrative proceedings and governmental regulation, especially in a foreign country, future financial and operational results, competition, general economic conditions, proposed transactions that are not legally binding obligations of the company and the ability to manage and continue growth. Should one or more of these risks or uncertainties materialize, or should underlying assumptions prove incorrect, actual outcomes may vary materially from those indicated. Important factors that could cause actual results to differ materially from the forward-looking statements we make in this news release include the introduction of new technology, market conditions and those set forth in reports or documents we file from time to time with the SEC. We undertake no obligation to revise or update such statements to reflect current events or circumstances after the date hereof or to reflect the occurrence of unanticipated events.

Media Contact:

Item 9 Labs
Jayne Levy, Director of Communications
Email: Jayne@unityrd.com

Investor Contact:

ClearThink
Email: nyc@clearthink.capital

SOURCE: Item 9 Labs Corp.